Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-15), Onward Medical NV's 12-1 Month Momentum % is N/A%.
The industry rank for Onward Medical NV's 12-1 Month Momentum % or its related term are showing as below:
CHIX:ONWDb's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -17.58 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Onward Medical NV (CHIX:ONWDb) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Onward Medical NV 12-1 Month Momentum % Related Terms
CHIX:ONWDB vs VRTX, REGN, RVMD: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Onward Medical NV's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onward Medical NV 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Onward Medical NV's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Onward Medical NV's 12-1 Month Momentum % falls into.
Onward Medical NV (CHIX:ONWDb) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onward Medical NV (CHIX:ONWDB) has a 12-1 Month Momentum % of N/A% as of Aug. 15, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Onward Medical NV and its competitors. According to the industry distribution chart, Onward Medical NV ranks #956 out of 1354 companies in the Biotechnology industry, placing it in the top 70.6%.
Is Onward Medical NV's 12-1 Month Momentum % too high?
Onward Medical NV's current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Onward Medical NV ranks #956 out of 1354 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Onward Medical NV has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Onward Medical NV's 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Onward Medical NV ranks #956 out of 1354 companies for 12-1 Month Momentum %. This places Onward Medical NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Onward Medical NV and its competitors. Onward Medical NV's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onward Medical NV stock overvalued right now?
Onward Medical NV (CHIX:ONWDB) has a current 12-1 Month Momentum % of N/A%. The stock's GF Value™ is €361.93, compared to a current price of €6.12 — trading 98.3% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Onward Medical NV's overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Onward Medical NV (CHIX:ONWDB), the current 12-1 Month Momentum % is N/A% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Onward Medical NV (CHIX:ONWDB) Overvalued in 2026?
Based on GuruFocus' analysis, Onward Medical NV stock appears to be undervalued.
The current stock price of €6.12 is trading 98.3% below its estimated GF Value™ of €361.93.
Key valuation signals for CHIX:ONWDB:
12-1 Month Momentum %: N/A%
GF Value™: €361.93 vs. price of €6.12 (98.3% below fair value)
No single metric tells the full story. See the CHIX:ONWDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Onward Medical NV is developing and commercializing therapies to enable functional recovery for people with Spinal Cord Injury (SCI). The company's technology platforms are based on ONWARD ARC Therapy (ARC Therapy), targeted, programmed electrical stimulation of the spinal cord designed to restore movement, independence, and health in people with SCI.
38GF Score
Get the complete analysis for CHIX:ONWDB
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONWDB has been successfully added to your 
